Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 3 Results

Intervention Indication Therapeutic Area Year Actions
Tucatinib with trastuzumab emtansine for treating unresectable, locally advanced or metastatic HER2 positive breast cancer Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) , Tucatinib (ONT-380) Breast cancer Breast Cancer 2022 View  |  Download
Trastuzumab emtansine in combination with pertuzumab for HER2-positive early breast cancer - adjuvant therapy Pertuzumab (Perjeta; R-1273) , Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) Breast cancer Breast Cancer 2019 View  |  Download
Trastuzumab Emtansine for HER2-positive breast cancer - adjuvant Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) Breast cancer Breast Cancer 2018 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications